HIGHLIGHTS
- who: Mei-Mei Zheng from the (UNIVERSITY) have published the paper: Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases, in the Journal: (JOURNAL)
- what: The authors focused on patients with EGFR-mutated NSCLC who were heavily treated and then had LM as the progression site on osimertinib. The authors presented CSF-private resistant mechanisms to osimertinib in patients with LM. In a word, the study provided some evidence of continuing osimertinib with additional therapy as an alternative when the standard of care was exhausted in LM.
- how: These . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.